DNA primase Inhibitors
1 drugsAbout DNA primase
DNA primase is an enzyme essential for DNA replication. As a specialized RNA polymerase, it synthesizes short RNA primers, providing a starting point for DNA polymerases to initiate DNA strand replication.
DNA primase represents a potential drug target due to its fundamental role in DNA synthesis, particularly in rapidly dividing cells. However, there is currently no genetic evidence available linking DNA primase to specific diseases.
Currently, one FDA-approved drug, Fludarabine Phosphate, targets DNA primase as a small molecule. This drug, marketed by Hikma, was first approved in 2003 and is used in 'other' therapeutic areas.
Top DNA primase Drugs
Hikma is the only company with an approved drug targeting DNA primase.
The limited number of players suggests a low competitive intensity but potentially high entry barriers.
DNA primase Clinical Trials 927 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on DNA primase. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 550 | 136 | 129 | 272 | 51% |
| Phase 2 | 326 | 107 | 94 | 123 | 53% |
| Phase 3 | 46 | 17 | 6 | 23 | 74% |
| Phase 4 | 5 | 3 | 2 | 0 | 60% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 256 (76 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on DNA primase. A trial counts if an approved drug acting on DNA primase is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.